<p>Assenagon Asset Management S.A. 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免费报告）股票中的持仓降低了 28.4%。该机构投资者在此期间出售了 26,119 股后，持有该公司 65,756 股股票。Assenagon Asset Management S.A. 在最近一个季度末持有 Protagonist Therapeutics 0.11% 的股份，价值 4,368,000 美元。</p>
<ul>
<li>强生的并购策略才是投资者真正关注的故事</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也买卖了该公司的股票。Guggenheim Capital LLC 在第二季度将其在 Protagonist Therapeutics 的持仓增加了 1.6%。Guggenheim Capital LLC 目前持有该公司 19,208 股股票，价值 1,062,000 美元，此前在上个季度又增持了 303 股。Bessemer Group Inc. 在第二季度将其在 Protagonist Therapeutics 的股份提高了 171.0%。Bessemer Group Inc. 目前持有该公司 504 股股票，价值 28,000 美元，此前在上个季度又购买了 318 股。汇丰控股 PLC 在第一季度将其在 Protagonist Therapeutics 的股份提高了 4.1%。汇丰控股 PLC 目前持有该公司 8,458 股股票，价值 405,000 美元，此前在上个季度又增持了 330 股。未来资产全球投资有限公司在第二季度将其在 Protagonist Therapeutics 的持仓增加了 16.6%。未来资产全球投资有限公司目前持有该公司 2,394 股股票，价值 132,000 美元，此前在上个季度又购买了 340 股。最后，未来资产全球 ETF 持有有限公司在第一季度将其在 Protagonist Therapeutics 的股份增加了 0.9%。未来资产全球 ETF 持有有限公司目前持有该公司 37,403 股股票，价值 1,810,000 美元，此前在上个季度又增持了 348 股。目前，98.63% 的股票由机构投资者和对冲基金持有。</p>
<h2>Protagonist Therapeutics 的内部买卖</h2>
<p>在 Protagonist Therapeutics 的其他消息中，董事 William D. Waddill 于 10 月 10 日星期五出售了 12,000 股 Protagonist Therapeutics 股票。该股票以平均价格 81.62 美元出售，总价值为 979,440.00 美元。交易后，该董事直接持有该公司 5,130 股股票，价值约 418,710.60 美元。此交易代表其持仓减少了 70.05%。该出售在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有该公司 4.90% 的股票。</p>
<h2>Protagonist Therapeutics 股票表现</h2>
<ul>
<li>这只小型生物科技股票是否还有（更多）大幅上涨的空间？</li>
</ul>
<p>NASDAQ PTGX 周一开盘价为 86.05 美元。该公司的 50 日移动平均线为 83.39 美元，200 日移动平均线为 66.53 美元。Protagonist Therapeutics, Inc. 的一年最低价为 33.70 美元，一年最高价为 96.54 美元。该公司的市值为 53.8 亿美元，市盈率为 138.79，贝塔值为 2.19。</p>
<p>Protagonist Therapeutics（NASDAQ:PTGX - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告的每股收益（EPS）为（0.62）美元，低于分析师一致预期的（0.59）美元，差距为（0.03）美元。该公司本季度的收入为 471 万美元，而分析师预期为 541 万美元。Protagonist Therapeutics 的股本回报率为 6.86%，净利润率为 21.94%。研究分析师预测 Protagonist Therapeutics, Inc. 本年度将发布 2.43 美元的每股收益。</p>
<h2>分析师评级上调和下调</h2>
<p>几位分析师最近对该股票发表了看法。BTIG Research 在 10 月 28 日星期二的研究报告中重申了 &#34;买入&#34; 评级，并设定了 82.00 美元的目标价。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Protagonist Therapeutics 的 &#34;卖出（d+）&#34; 评级。HC Wainwright 在 10 月 8 日星期三重新发布了 &#34;买入&#34; 评级，并对 Protagonist Therapeutics 的股票设定了 80.00 美元的目标价。花旗集团在 12 月 8 日星期一将 Protagonist Therapeutics 的目标价从 98.00 美元上调至 115.00 美元，并给予该股票 &#34;买入&#34; 评级。最后，摩根大通将 Protagonist Therapeutics 的目标价从 68.00 美元上调至 81.00 美元，并在 11 月 7 日星期五的报告中给予该公司 &#34;增持&#34; 评级。一位股票研究分析师对该股票给予了强烈买入评级，十一位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Protagonist Therapeutics 目前的平均评级为 &#34;适度买入&#34;，共识目标价为 85.08 美元。</p>
<p><strong>获取我们关于 Protagonist Therapeutics 的最新股票报告</strong></p>
<h2>Protagonist Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Protagonist Therapeutics, Inc NASDAQ: PTGX 是一家临床阶段的生物制药公司，专注于开发新型口服给药的肽类疗法，针对免疫介导和其他严重疾病。该公司利用其专有的 Peptide 2.0 平台设计靶向 G 蛋白偶联受体和细胞因子受体的肽，旨在将生物制剂的效力与口服给药的便利性相结合。Protagonist 的方法旨在解决注射疗法作为标准治疗的领域中的未满足医疗需求。</p>
<p>其主要项目之一是 PTG-100，一种口服 α4β7 整合素拮抗剂，旨在阻止白细胞迁移到溃疡性结肠炎和克罗恩病的肠道中。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Protagonist Therapeutics</li>
<li>我不应该把这个发给你</li>
<li>揭示：美国刚刚解锁了一个 500 万亿的资产</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>他们嘲笑 30 美元。他们不会再嘲笑 70 美元。</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Protagonist Therapeutics 吗？</h2>
<p>在你考虑 Protagonist Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Protagonist Therapeutics 并不在名单上。</p>
<p>虽然 Protagonist Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Protagonist治疗

<p>Assenagon Asset Management S.A. 在第三季度将其在 Protagonist Therapeutics, Inc. 的持股减少了 28.4%，目前持有 65,756 股，价值 437 万美元。其他机构投资者也调整了他们的持股。Protagonist 的股票开盘价为 86.05 美元，市值为 53.8 亿美元。分析师的评级不一，有些分析师上调了他们的目标价格</p>

<p>Assenagon Asset Management S.A. lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 28.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,756 shares of the company's stock after selling 26,119 shares during the period. Assenagon Asset Management S.A. owned 0.11% of Protagonist Therapeutics worth $4,368,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免费报告）股票中的持仓降低了 28.4%。该机构投资者在此期间出售了 26,119 股后，持有该公司 65,756 股股票。Assenagon Asset Management S.A. 在最近一个季度末持有 Protagonist Therapeutics 0.11% 的股份，价值 4,368,000 美元。</p>
</div><ul>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>强生的并购策略才是投资者真正关注的故事</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Guggenheim Capital LLC boosted its position in shares of Protagonist Therapeutics by 1.6% during the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company's stock worth $1,062,000 after acquiring an additional 303 shares in the last quarter. Bessemer Group Inc. lifted its stake in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company's stock worth $28,000 after purchasing an additional 318 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Protagonist Therapeutics by 4.1% during the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company's stock worth $405,000 after purchasing an additional 330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Protagonist Therapeutics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company's stock valued at $132,000 after purchasing an additional 340 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Protagonist Therapeutics by 0.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock valued at $1,810,000 after purchasing an additional 348 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也买卖了该公司的股票。Guggenheim Capital LLC 在第二季度将其在 Protagonist Therapeutics 的持仓增加了 1.6%。Guggenheim Capital LLC 目前持有该公司 19,208 股股票，价值 1,062,000 美元，此前在上个季度又增持了 303 股。Bessemer Group Inc. 在第二季度将其在 Protagonist Therapeutics 的股份提高了 171.0%。Bessemer Group Inc. 目前持有该公司 504 股股票，价值 28,000 美元，此前在上个季度又购买了 318 股。汇丰控股 PLC 在第一季度将其在 Protagonist Therapeutics 的股份提高了 4.1%。汇丰控股 PLC 目前持有该公司 8,458 股股票，价值 405,000 美元，此前在上个季度又增持了 330 股。未来资产全球投资有限公司在第二季度将其在 Protagonist Therapeutics 的持仓增加了 16.6%。未来资产全球投资有限公司目前持有该公司 2,394 股股票，价值 132,000 美元，此前在上个季度又购买了 340 股。最后，未来资产全球 ETF 持有有限公司在第一季度将其在 Protagonist Therapeutics 的股份增加了 0.9%。未来资产全球 ETF 持有有限公司目前持有该公司 37,403 股股票，价值 1,810,000 美元，此前在上个季度又增持了 348 股。目前，98.63% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling at Protagonist Therapeutics</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 的内部买卖</h2>
</div><p>In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the transaction, the director directly owned 5,130 shares in the company, valued at approximately $418,710.60. This trade represents a 70.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.90% of the company's stock.</p>
<div class="lb-trans"><p>在 Protagonist Therapeutics 的其他消息中，董事 William D. Waddill 于 10 月 10 日星期五出售了 12,000 股 Protagonist Therapeutics 股票。该股票以平均价格 81.62 美元出售，总价值为 979,440.00 美元。交易后，该董事直接持有该公司 5,130 股股票，价值约 418,710.60 美元。此交易代表其持仓减少了 70.05%。该出售在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有该公司 4.90% 的股票。</p>
</div><h2>Protagonist Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 股票表现</h2>
</div><ul>
<li>Are (More) Big Gains Ahead for This Small Cap Biotech Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>这只小型生物科技股票是否还有（更多）大幅上涨的空间？</li>
</ul>
</div><p>NASDAQ PTGX opened at $86.05 on Monday. The firm's fifty day moving average is $83.39 and its two-hundred day moving average is $66.53. Protagonist Therapeutics, Inc. has a one year low of $33.70 and a one year high of $96.54. The firm has a market cap of $5.38 billion, a PE ratio of 138.79 and a beta of 2.19.</p>
<div class="lb-trans"><p>NASDAQ PTGX 周一开盘价为 86.05 美元。该公司的 50 日移动平均线为 83.39 美元，200 日移动平均线为 66.53 美元。Protagonist Therapeutics, Inc. 的一年最低价为 33.70 美元，一年最高价为 96.54 美元。该公司的市值为 53.8 亿美元，市盈率为 138.79，贝塔值为 2.19。</p>
</div><p>Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to analysts' expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Protagonist Therapeutics（NASDAQ:PTGX - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告的每股收益（EPS）为（0.62）美元，低于分析师一致预期的（0.59）美元，差距为（0.03）美元。该公司本季度的收入为 471 万美元，而分析师预期为 541 万美元。Protagonist Therapeutics 的股本回报率为 6.86%，净利润率为 21.94%。研究分析师预测 Protagonist Therapeutics, Inc. 本年度将发布 2.43 美元的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Several analysts have recently weighed in on the stock. BTIG Research restated a &#34;buy&#34; rating and set a $82.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reissued a &#34;buy&#34; rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, October 8th. Citigroup raised their price objective on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, December 8th. Finally, JPMorgan Chase &amp; Co. boosted their target price on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $85.08.</p>
<div class="lb-trans"><p>几位分析师最近对该股票发表了看法。BTIG Research 在 10 月 28 日星期二的研究报告中重申了 &#34;买入&#34; 评级，并设定了 82.00 美元的目标价。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Protagonist Therapeutics 的 &#34;卖出（d+）&#34; 评级。HC Wainwright 在 10 月 8 日星期三重新发布了 &#34;买入&#34; 评级，并对 Protagonist Therapeutics 的股票设定了 80.00 美元的目标价。花旗集团在 12 月 8 日星期一将 Protagonist Therapeutics 的目标价从 98.00 美元上调至 115.00 美元，并给予该股票 &#34;买入&#34; 评级。最后，摩根大通将 Protagonist Therapeutics 的目标价从 68.00 美元上调至 81.00 美元，并在 11 月 7 日星期五的报告中给予该公司 &#34;增持&#34; 评级。一位股票研究分析师对该股票给予了强烈买入评级，十一位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Protagonist Therapeutics 目前的平均评级为 &#34;适度买入&#34;，共识目标价为 85.08 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Protagonist Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Protagonist Therapeutics 的最新股票报告</strong></p>
</div><h2>Protagonist Therapeutics Profile</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.</p>
<div class="lb-trans"><p>Protagonist Therapeutics, Inc NASDAQ: PTGX 是一家临床阶段的生物制药公司，专注于开发新型口服给药的肽类疗法，针对免疫介导和其他严重疾病。该公司利用其专有的 Peptide 2.0 平台设计靶向 G 蛋白偶联受体和细胞因子受体的肽，旨在将生物制剂的效力与口服给药的便利性相结合。Protagonist 的方法旨在解决注射疗法作为标准治疗的领域中的未满足医疗需求。</p>
</div><p>Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.</p>
<div class="lb-trans"><p>其主要项目之一是 PTG-100，一种口服 α4β7 整合素拮抗剂，旨在阻止白细胞迁移到溃疡性结肠炎和克罗恩病的肠道中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Protagonist Therapeutics</li>
<li>I Shouldn't Be Sending You This</li>
<li>REVEALED: America just unlocked a $500 trillion asset</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>They Laughed at $30. They Won’t Laugh at $70.</li>
<li>How Long Will $1M Last in Retirement?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Protagonist Therapeutics</li>
<li>我不应该把这个发给你</li>
<li>揭示：美国刚刚解锁了一个 500 万亿的资产</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>他们嘲笑 30 美元。他们不会再嘲笑 70 美元。</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PTGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Protagonist Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Protagonist Therapeutics 吗？</h2>
</div><p>Before you consider Protagonist Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Protagonist Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Protagonist Therapeutics 并不在名单上。</p>
</div><p>While Protagonist Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Protagonist Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon Asset Management S.A. 减少了其在 Protagonist 治疗公司 $PTGX 的股票持有量